Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy
/in Dendritic Cells, International PublicationsThe evolving role of dendritic cells in cancer therapy
/in Dendritic Cells, International PublicationsDendritic Cells-based Vaccine and Immune Monitoring for Hepatocellular Carcinoma
/in Dendritic Cells, Hepatocellular Carcinoma, International PublicationsDendritic cells pulsed with an anti-idiotype antibody mimicking Her-2/neu induced protective antitumor immunity in two lines of Her-2/neu transgenic mice
/in Breast Cancer, Dendritic Cells, International PublicationsConsolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma
/in Dendritic Cells, International Publications, Malignant Pleural MesotheliomaPotent anti-tumor responses to immunization with dendritic cells loaded with tumor tissue and an NKT cell ligand
/in Dendritic Cells, International PublicationsGeneration of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28
/in Dendritic Cells, International PublicationsWhat’s the place of immunotherapy in malignant mesothelioma treatments?
/in Dendritic Cells, International Publications, Malignant Pleural MesotheliomaPresentation of tumour antigens by dendritic cells and challenges faced
/in Dendritic Cells, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer